Stock Taper
SCREENER COMPARE ANY 2 STOCKS
NVCT
NUVECTIS PHARMA, INC.
NASDAQ
$23.73
▼ DOWN 5.80% (-1.46)

KEY STATISTICS

Market Cap$629.71 M
52w High$29.27
52w Low$5.55
Dividend Yield—
Frequency—
P/E-18.11
Volume137.20K
Shares Out.26.54M

COMPANY

LEADERSHIP

Ron Bentsur
CHIEF EXECUTIVE
Ron Bentsur

COMPENSATION 2026

Salary$653,987
Stock Awards$1,395,000
Incentive Plan Pay$0
All Other Comp.$0
Total$2,588,526

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 4, 2022
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
16

PRICE TARGET

Target High$39.00
Target Low$33.00
Target Median$36.00
Target Consensus$36.00

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.—
NOV
3
TUE

PRICE

$23.73 ▼ DOWN 5.80% (−$1.46)
$23.25$24.00$24.75$25.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM23.73

About Nuvectis Pharma, Inc.

https://www.nuvectis.com ↗

Nuvectis Pharma, Inc. is a biopharmaceutical company founded in 2020 in Fort Lee, NJ, developing precision cancer medicines like NXP800 and NXP900 to address unmet medical needs.

INDUSTRY

Biotechnology

A PRODUCT NUVECTIS PHARMA, INC. IS KNOWN FOR

NXP900
NXP900

Nuvectis Pharma's lead investigational oral SFK inhibitor is in Phase 1b trials for advanced solid tumors, representing the company's primary focus in ongoing clinical development.

COMPETITORS

COMPETITOR
AVBP COMPARE
BDTX COMPARE
NU NUVL COMPARE
RCUS COMPARE
SMMT COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
56
LISTED HERE
9
RANKED BY POSITION SIZE
VTS.AX
0.00% · 650.5K
IWM
0.01% · 431.7K
FESM
0.04% · 96.8K
ZPRR.DE
0.01% · 21.3K
GSSC
0.04% · 15.9K
XRSU.L
0.01% · 15.6K
RSSL
0.01% · 8.1K
URTY
0.01% · 693
SC0K.DE
0.01% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
16.07%
HOLDERS
67
TOP 12 OF 67 · RANKED BY POSITION SIZE
Vanguard Group Inc
845.5K sh · $6.38M
Blackrock, Inc.
782.8K sh · $5.91M
Iridian Asset Management LLC/Ct
651.8K sh · $5.04M
Ronit Capital Llp
562.5K sh · $3.99M
Geode Capital Management, LLC
384.1K sh · $2.97M
Baldwin Brothers LLC/Ma
378.6K sh · $2.93M
State Street Corp
166.5K sh · $1.29M
Susquehanna International Group, Llp
134.2K sh · $1.01M
Northern Trust Corp
124.2K sh · $960.16K
Blackrock Inc.
83.4K sh · $528K
Citadel Advisors LLC
78.4K sh · $606.23K
Oppenheimer & Co Inc
73.6K sh · $568.66K

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: VICE PRESIDENT, FINANCE
Carson Michael J.
Purchase · 30.0K shares
2026-08-03
★
10 PERCENT OWNER
Mosseri Marlio Charles
Purchase · 50.0K shares
2026-06-30
★
DIRECTOR, 10 PERCENT OWNER, OFFICER: CHAIRMAN & CEO
BENTSUR RON
Purchase · 12.5K shares
2026-06-30
★
DIRECTOR
Hoberman Kenneth
Purchase · 35.0K shares
2026-06-11

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
2 GRADES IN THE LAST 12 MONTHS
Roth Capital BUY HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
CGEN$2.60COMPARE
TNXP$13.59COMPARE
IPHA$2.22COMPARE
MOLN$4.50COMPARE
MIST$1.16COMPARE
CRDF$0.94COMPARE
RANI$0.84COMPARE